Quantbot Technologies LP Has $98,000 Position in Fulgent Genetics, Inc. (NASDAQ:FLGT)

Quantbot Technologies LP trimmed its stake in shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) by 38.9% in the third quarter, Holdings Channel.com reports. The firm owned 4,494 shares of the company’s stock after selling 2,858 shares during the quarter. Quantbot Technologies LP’s holdings in Fulgent Genetics were worth $98,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in FLGT. Asset Dedication LLC bought a new stake in shares of Fulgent Genetics during the second quarter worth $33,000. nVerses Capital LLC acquired a new stake in shares of Fulgent Genetics during the 2nd quarter valued at $43,000. Signaturefd LLC boosted its holdings in shares of Fulgent Genetics by 103.6% during the 2nd quarter. Signaturefd LLC now owns 2,225 shares of the company’s stock valued at $44,000 after acquiring an additional 1,132 shares in the last quarter. Canada Pension Plan Investment Board bought a new stake in Fulgent Genetics during the 2nd quarter worth $63,000. Finally, Gladius Capital Management LP acquired a new position in Fulgent Genetics in the 3rd quarter worth about $81,000. Institutional investors own 48.06% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Piper Sandler reduced their price target on Fulgent Genetics from $26.00 to $22.00 and set a “neutral” rating on the stock in a report on Monday, November 11th. StockNews.com downgraded shares of Fulgent Genetics from a “hold” rating to a “sell” rating in a research report on Wednesday, November 27th.

Fulgent Genetics Stock Up 2.0 %

Shares of NASDAQ:FLGT opened at $20.09 on Friday. The firm has a market cap of $614.55 million, a P/E ratio of -3.64 and a beta of 1.42. Fulgent Genetics, Inc. has a 12-month low of $16.56 and a 12-month high of $30.68. The business has a fifty day simple moving average of $19.65 and a 200 day simple moving average of $21.03.

Insider Activity

In other news, CEO Ming Hsieh sold 2,227 shares of the company’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $18.26, for a total value of $40,665.02. Following the sale, the chief executive officer now directly owns 703,711 shares of the company’s stock, valued at approximately $12,849,762.86. This represents a 0.32 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Over the last quarter, insiders sold 3,413 shares of company stock valued at $62,321. Company insiders own 31.76% of the company’s stock.

About Fulgent Genetics

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.